Preliminary Assessment of [18F]BL40 in PET/CT Scans

Official record

Identifier

NCT06224309

Recruiting locations

country

Canada

Interventions studied

18F-BL40 PET/CT18F-FDG PET/CTRoutine Blood Draw - Phase 1 only

Lead sponsor

British Columbia Cancer Agency

Target enrolment

30 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Jan 25, 2024

Last updated on the registry

Oct 1, 2026

Age

19 Years – 100 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Age ≥19 years
2. Life expectancy ≥3 months
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
4. Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:

   * Diffuse large B-Cell lymphoma
   * Multiple myeloma
   * Mantle cell lymphoma
   * Marginal zone lymphoma
   * Chronic lymphocytic leukemia/small cell lymphoma
   * Waldenström Macroglobulinemia

Exclusion Criteria:

1. Pregnant or breast-feeding
2. Medically unstable (e.g., acute illness, unstable vital signs)
3. Unable to lie supine for the duration of imaging
4. Unable to provide written consent
5. Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)
6. Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic \[18F\]BL40 or any of its excipients.

Indexed under

Leukemia